Evoke Pharma announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a continuation of US Patent No. 11,517,545 (“Treatment of Moderate and Severe Gastroparesis”), which was issued in 2022 and which covers the use of Evoke’s Gimoti metoclopramide nasal spray. The company says that it plans to list the patent, which will expire in December 2036, in the Orange Book and that it has also filed an additional continuation application.
Gimoti intranasal metoclopramide was approved by the FDA in June 2020 for the treatment of diabetic gastroparesis. The USPTO has also previously issued a number of patents covering the formulation of the nasal spray.
Evoke CEO Matt D’Onofrio commented, “This new patent allowance adds meaningful value to the Gimorti franchise by reinforcing protection around how and in whom the therapy is used. Backed by extensive market research, Gimoti continues to stand out as an effective non-oral treatment for a disease that can compromise the effectiveness of pills due to slowed gastric absorption of oral medications. We remain focused on maximizing Gimoti’s potential as an effective patient-friendly treatment for diabetic gastroparesis.”
Read the Evoke Pharma press release
